Concerns Surround H1N1 Vaccine Which May Contain Thimerosal
By Shaun HeasleyA swine flu vaccine expected this fall is raising red flags because it will likely contain a preservative some link to autism despite scientific research repeatedly proving otherwise.
Government officials say they hope to have 160 million doses of a vaccine for swine flu, or H1N1, available by the fall when flu season is expected to kick in. A vaccine is currently going through clinical trials. Pregnant women, children and health care workers will be the first to be vaccinated.
Scientists say the swine flu vaccine will be similar to the flu vaccines provided annually with little fanfare. However, some consumer groups are reserved about the new vaccine because of the possibility that it could contain thimerosal in combination with a second additive in an effort to produce large quantities more quickly.
Furthermore, a vaccine offered to combat a different strain of the swine flu in the 1970s is linked to increased incidents of a neurological disorder.
But makers of the vaccine say they anticiptate manufacturing two versions, one with and one without thimerosal, which ought to ease some fears, reports ABC News. To read more click here.
Copyright © 2009 Disability Scoop, LLC. All Rights Reserved. For reprints and permissions click here.
How about the lobby…
Top All-Time Donors 1989-2008
58 Pfizer Inc $13,201,017
67 GlaxoSmithKline $10,892,244
84 Eli Lilly & Co $8,979,924
96 Bristol-Myers Squibb $7,282,437
All these companies donating money to the congress? And somebody dears to call people lunatics for distrusting CDC/FDA?
2003 study has been dismissed and flawed, and other studies since been labeled biased due to conflict of interest.
I see it time and time again, people trying to discredit somebody asking one simple question – why is thimerosal still in the vaccines?
2004 study:
Conflicts of interest in new CDC Thimerosal study of 2004:
Dr. Thompson – former employee of Merck;
Dr. Marcy, receiving consulting fees from Merck, Sanofi Pasteur, GlaxoSmithKline, and MedImmune;
Dr. Jackson, receiving grant support from Wyeth, Sanofi Pasteur, GlaxoSmithKline, and Novartis, lecture fees from Sanofi Pasteur, and consulting fees from Wyeth and Abbott and serving as a consultant to the FDA Vaccines and Related Biological Products Advisory Committee;
Dr. Lieu, serving as a consultant to the CDC Advisory Committee on Immunization Practices;
Dr. Black, receiving consulting fees from MedImmune, GlaxoSmithKline, Novartis, and Merck and grant support from MedImmune, GlaxoSmithKline, Aventis, Merck, and Novartis;
and Dr. Davis receiving consulting fees from Merck and grant support from Merck and GlaxoSmithKline.
Post a Comment
You must be logged in to post a comment. Click here to log in or register.